# **Advanced Molecular Analysis of Pyrroloquinoline Quinone: Evaluating Mitochondrial Biogenesis, Temporal Pharmacokinetics, and the Persistence of Regulatory Downregulations Post-Cessation**

The chemical landscape of mitochondrial medicine has been significantly altered by the identification and subsequent clinical investigation of pyrroloquinoline quinone (PQQ), a tricyclic ortho-quinone that functions as a critical redox biofactor.1 Originally discovered in the 1960s as a cofactor for bacterial dehydrogenases, PQQ—formally designated as 4,5-dihydro-4,5-dioxo-1H-pyrrolo\[2,3-f\]quinoline-2,7,9-tricarboxylic acid—has emerged as a "vitamin-like" substance essential for mammalian growth, development, and energetic homeostasis.1 A central question within contemporary metabolic research, and a point of significant interest for clinical practitioners, is the temporal stability of the physiological adaptations induced by PQQ supplementation.6 Specifically, the inquiry seeks to determine if the cessation of PQQ intake triggers a negative downregulation of endogenous mitochondrial systems or if the observed improvements in metabolic flexibility and antioxidant defense represent a permanent recalibration of cellular function.1 This report provides an exhaustive evaluation of PQQ's molecular mechanisms, its pharmacokinetic profile, and the evidence surrounding the reversal or persistence of its biological effects once the substance is withdrawn from the system.

## **Biochemical Identity and Evolutionary Significance**

The unique molecular architecture of PQQ facilitates its role as a potent redox cycler, characterized by an aromatic tricyclic structure that allows for extreme stability during electron transfer reactions.1 Unlike many dietary antioxidants that are rapidly consumed or polymerized, PQQ can undergo approximately 20,000 cycles of reduction and oxidation before it reaches metabolic degradation.8 This molecular resilience is biologically significant, as it permits PQQ to influence cellular signaling at nanomolar concentrations, a potency estimated to be 100 to 1,000 times greater than that of ascorbic acid or various polyphenolic compounds when measured on a molar basis.1

PQQ is found in trace amounts throughout the natural world, including in fruits, vegetables, and fermented foods, as well as in human breast milk at concentrations similar to established vitamins like riboflavin and folate.1 Some researchers have hypothesized an evolutionary role for PQQ in the development of life on Earth, noting its presence in interstellar stardust.4 While humans and the bacteria within the human digestive tract appear unable to synthesize PQQ de novo, the substance is widely distributed in mammalian tissues, suggesting it is a vital micronutrient obtained through the diet.2

### **Comparative Nutrient Density and Natural Sources**

| Food Source | PQQ Concentration Range (μg/kg) | Nutritional Context |
| :---- | :---- | :---- |
| Fermented Soybeans (Natto) | ![][image1] \- ![][image2] | Highest naturally occurring levels |
| Human Breast Milk | ![][image3] \- ![][image4] | Critical for neonatal development |
| Green Tea | ![][image5] \- ![][image6] | Common dietary source |
| Spinach | ![][image7] \- ![][image6] | Baseline vegetable intake |
| Legume Seeds | ![][image8] | Moderate density |
| Kiwi Fruit | ![][image7] \- ![][image6] | Notable fruit source |

2

The absence of PQQ in experimental diets leads to a syndrome characterized by impaired growth, immune dysfunction, and reduced mitochondrial density, which is effectively reversed upon repletion with as little as 200 to 300 ![][image9]g of PQQ per kilogram of diet.1 This "deficiency-recovery" pattern strongly supports the classification of PQQ as an essential biofactor, even if it has not yet achieved formal vitamin status by all regulatory bodies.1

## **Molecular Mechanisms of Action: The Biogenesis Cascade**

The primary mechanism by which PQQ influences cellular health is the stimulation of mitochondrial biogenesis.10 This process is not merely a quantitative increase in mitochondrial number but a qualitative enhancement of the cell’s energetic capacity.10 The cascade begins with the activation of the cAMP response element-binding protein (CREB) through phosphorylation at the Serine 133 residue.10 Phosphorylated CREB subsequently binds to the promoter of the peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC-1$\\alpha$), which acts as the master regulator of mitochondrial metabolism.10

### **The PGC-1$\\alpha$ and Nrf2 Regulatory Axis**

PGC-1$\\alpha$ coordinates a sophisticated network of nuclear and mitochondrial gene expression.14 PQQ-induced biogenesis involves the upregulation of several downstream transcription factors:

1. **Nuclear Respiratory Factors (NRF-1 and NRF-2):** These factors regulate the expression of nuclear genes that encode mitochondrial proteins, including components of the electron transport chain.1  
2. **Mitochondrial Transcription Factor A (TFAM):** This protein is essential for the replication, maintenance, and transcription of mitochondrial DNA (mtDNA).1  
3. **Mitochondrial Transcription Factors B1 and B2 (TFB1M and TFB2M):** These factors facilitate the transcription of the mitochondrial genome.7

The efficacy of PQQ in this pathway is demonstrated by its ability to increase citrate synthase activity and the ratio of mitochondrial to nuclear DNA.10 Research indicates that these effects are dependent on the presence of PGC-1$\\alpha$; when PGC-1$\\alpha$ expression is reduced via small interfering RNA (siRNA), the biogenic effects of PQQ are abolished.7

Simultaneously, PQQ activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway, a critical component of the cellular antioxidant defense system.17 Nrf2 promotes the transcription of genes such as heme oxygenase-1 (HO-1) and various glutathione-related enzymes.17 The dual activation of PGC-1$\\alpha$ and Nrf2 creates a synergistic environment where the cell simultaneously generates more mitochondria and enhances its capacity to neutralize the reactive oxygen species (ROS) that are a natural byproduct of increased oxidative phosphorylation.14

### **Transcriptional Regulation and Mitochondrial Markers**

| Molecular Marker | Effect of PQQ Exposure | Physiological Impact |
| :---- | :---- | :---- |
| PGC-1$\\alpha$ | Increased mRNA/Protein | Enhanced master regulator activity |
| CREB (Ser133) | Increased Phosphorylation | Initiation of biogenic signaling |
| TFAM | Increased Expression | Enhanced mtDNA replication/maintenance |
| NRF-1 / NRF-2 | Increased Activation | Coordination of nuclear-mitochondrial genes |
| Citrate Synthase | Increased Activity | Marker of mitochondrial volume density |
| Cytochrome c Oxidase | Increased Activity | Enhanced respiratory capacity |

1

## **Pharmacokinetics: Absorption, Distribution, and Elimination**

Understanding whether PQQ induces lasting downregulations requires a granular analysis of its pharmacokinetic behavior in humans.21 Clinical studies using a crossover design have elucidated the metabolic trajectory of oral PQQ supplementation.21 When a single dose of 0.2 mg/kg body weight is ingested, PQQ is rapidly absorbed into the bloodstream.21

### **Human Pharmacokinetic Profile**

The peak plasma concentration (![][image10]) occurs between 2 and 3 hours post-ingestion, with serum levels increasing directly in proportion to the dose administered.21 The terminal half-life (![][image11]) of PQQ in humans is relatively short, typically ranging from 3 to 5 hours.21 This indicates that PQQ is cleared from the systemic circulation within approximately 24 hours of the final dose.21

Excretion occurs primarily through the renal pathway, with approximately 0.1% of the ingested dose appearing in the urine as non-derivatized PQQ.21 The rise and clearance of PQQ in the serum closely parallel its levels in the urine.21 Despite this rapid systemic clearance, PQQ’s effects on cellular signaling may persist longer due to its ability to form conjugates with intracellular proteins through Schiff base formation.8

### **Pharmacokinetic Parameters of Oral PQQ Supplementation**

| Parameter | Observed Value | Clinical Significance |
| :---- | :---- | :---- |
| Peak Plasma Time (![][image10]) | ![][image12] \- ![][image13] hours | Rapid onset of systemic availability |
| Serum Half-Life (![][image11]) | ![][image13] \- ![][image14] hours | Fast metabolic clearance |
| Urinary Recovery | ![][image15] | Indicates significant tissue uptake or metabolism |
| Daily Dose (Human Trial) | ![][image16] \- ![][image17] mg/kg | Translates to ![][image18] \- ![][image19] mg for a ![][image20] kg adult |
| Effective Range | ![][image21] \- ![][image22] nM (Serum) | Bioactive at very low concentrations |

8

The short half-life of PQQ is a critical factor in evaluating post-cessation effects.6 Because the substance does not accumulate in high concentrations in the blood or tissues over the long term, the risk of inducing a chronic, negative downregulation through persistent receptor over-stimulation or feedback inhibition is minimized.6

## **The Question of Persistence: Reversal and Withdrawal Kinetics**

The central inquiry regarding whether PQQ induces downregulations after stopping the substance is addressed by the "Takatsu and Owada" research series, which examined the kinetics of PQQ depletion and repletion in animal models.6

### **Mitochondrial Reversal in Adults**

In these studies, rats that were fed diets devoid of PQQ exhibited a reduction in mitochondrial content in the liver and muscle by approximately 10% to 20%.6 This effect was observed within a short timeframe, and upon re-introduction of PQQ, mitochondrial levels were restored within 12 to 36 hours.6 When these findings are scaled to human physiology, the withdrawal response—or the return of mitochondrial markers to their basal state—is estimated to occur within approximately one week following the cessation of supplementation.6

This process is not a "downregulation" in the sense of a pathological impairment; rather, it represents a return to the organism's basal energetic set point.6 The biogenic improvements stimulated by PQQ are transient and depend on the continued presence of the molecule to maintain the enhanced state of PGC-1$\\alpha$ activation.6 If the PQQ stimulus is removed, the cellular machinery naturally reverts to the density and activity levels dictated by the individual's underlying genetics, age, and habitual activity.6

### **Absence of Negative Feedback Loops**

A major concern with many supplements is the potential for feedback inhibition, where exogenous intake suppresses endogenous production.1 In the case of PQQ, humans appear to lack the capacity for endogenous synthesis, making the concept of feedback inhibition of its own production moot.1 Furthermore, research into the enzyme AASDH (once thought to be involved in human PQQ synthesis) showed that its mRNA levels are not negatively regulated by PQQ concentrations, which would typically occur if a feedback loop were present.8

Therefore, cessation of PQQ does not cause the body to "stop making its own," as it was already dependent on dietary sources for its supply.1 The only observed "downregulation" post-cessation is the cessation of the supplemental biogenic boost, returning the user to their baseline physiological status without a rebound "crash" below that baseline.1

## **Therapeutic Downregulation: Managing Pathological States**

While PQQ does not cause deleterious downregulations post-cessation, it is specifically valued for its ability to induce *beneficial* downregulations of pathological systems during active use.22

### **Modulation of the NMDA Receptor**

PQQ acts as a redox-active modulator of the N-methyl-D-aspartate (NMDA) receptor, a subtype of glutamate receptor involved in neurotoxicity and seizures.26 It oxidizes the redox site of the NMDA receptor, which reduces the frequency of the receptor's ion channel opening without completely blocking it.26 This leads to a "therapeutic downmodulation" of glutamatergic over-excitation.26

Unlike pharmacological NMDA antagonists, which can have significant side effects by blocking physiological signaling, PQQ’s oxidative modulation is reversible and does not appear to alter long-term receptor density or induce a compensatory upregulation after withdrawal.26 This mechanism allows PQQ to provide neuroprotection against excitotoxicity during times of stress (such as stroke or seizure) while allowing normal brain function to continue.26

### **Neuroprotective and Anti-inflammatory Downregulations**

In models of cognitive impairment and aging, PQQ has been shown to downregulate several markers of degeneration:

1. **Phosphorylated Tau (p-Tau):** PQQ reduces the levels of hyperphosphorylated Tau protein in the hippocampus, a key driver of Alzheimer's disease pathology.3  
2. **Phosphorylated Akt (p-Akt):** In specific models of neurotoxicity induced by D-galactose, PQQ downregulates the over-expressed p-Akt to restore balance to the GSK-3$\\beta$ signaling pathway.25  
3. **Pro-inflammatory Cytokines:** PQQ significantly reduces systemic and tissue-level expression of CRP, IL-6, and TNF\-![][image23].19  
4. **Nitric Oxide and iNOS:** PQQ pretreatment attenuates the LPS-induced production of nitric oxide (NO) and the expression of inducible nitric oxide synthase (iNOS) in microglia.32

These downregulations are viewed as corrective rather than inhibitory to normal physiology.25 The clinical evidence suggests that these markers return toward their (often elevated) pathological baseline if the supplement is stopped, rather than dropping into a state of deficiency.6

### **Downregulation of Pathological Markers during PQQ Administration**

| Marker | Effect of PQQ | Context | Physiological Outcome |
| :---- | :---- | :---- | :---- |
| C-Reactive Protein (CRP) | Decreased | Human Serum | Reduced systemic inflammation |
| Interleukin-6 (IL-6) | Decreased | Human Serum | Lowered inflammatory stress |
| MDA (Malondialdehyde) | Decreased | Plasma / Liver | Reduced lipid peroxidation |
| p-Tau Protein | Downregulated | Hippocampus | Protection against neurofibrillary tangles |
| NMDA Receptor Activity | Downmodulated | Cortical Neurons | Prevention of excitotoxicity |
| CUL3 Protein | Downregulated | Kupffer Cells | Alleviation of hepatic fibrosis |

19

## **Developmental Programming: Persistent and Permanent Changes**

The most significant exception to the "transient reversal" rule occurs when PQQ is administered during critical windows of development.33

### **Maternal Supplementation and Epigenetic Resilience**

Research into "developmental programming" has shown that when PQQ is provided to obese dams during pregnancy and lactation, the benefits to the offspring persist well into adulthood, long after they have ceased receiving PQQ.33 These offspring exhibit:

* A persistent reduction in hepatic lipids and ceramides.33  
* A long-term downregulation of pro-inflammatory genes (e.g., *Nos2*, *Nlrp3*, *Il6*).33  
* An enduring increase in the expression of genes associated with fatty acid oxidation.33

This phenomenon suggests that PQQ may permanently "downregulate" the developmental risk of metabolic diseases through epigenetic mechanisms or by establishing a higher basal level of mitochondrial function during the formation of organ systems.1 In this specific context, the answer to whether PQQ induces downregulations (or upregulations) *after* stopping the substance is a qualified yes, but these changes are health-promoting and appear to be a permanent modification of the metabolic program rather than a withdrawal effect.33

## **Safety, Toxicology, and Clinical Indices**

The safety profile of PQQ is exceptionally robust, as evidenced by multiple toxicity studies and human clinical trials.3

### **Toxicological Thresholds**

In sub-chronic toxicity studies (90 days) conducted on Wistar rats, no evidence of systemic toxicity was found at doses up to 600 mg/kg body weight per day.36 All clinical indices, including hematology, clinical chemistry, neurological evaluations, and reproductive hormone levels, remained within normal ranges.36

| Study Type | Dose / Condition | Finding |
| :---- | :---- | :---- |
| Acute Oral LD50 (Male Rat) | ![][image24] mg/kg | Very low acute toxicity |
| 90-Day Sub-chronic (Rat) | ![][image25] mg/kg/day | NOAEL (No Observed Adverse Effect Level) |
| Human Trial (24 weeks) | ![][image22] mg/day | No adverse clinical effects reported |
| Human Standard serving | ![][image19] mg/day | Consistent with ![][image17] mg/kg BW |
| In Vitro Cytotoxicity | ![][image26] ![][image9]M | No effect on primary microglia viability |

3

Clinical trials in humans have further confirmed that PQQ supplementation does not adversely alter standard metabolic indices such as cholesterol, glucose, triglycerides, or liver enzymes.22 Instead, it tends to normalize markers that are out of balance due to oxidative stress or chronic inflammation.22

## **Metabolic Adaptations and Physical Performance**

Beyond its role in the brain, PQQ influences systemic metabolism and physical function, particularly in skeletal muscle.19

### **Muscle Strength and Physical Function**

A 12-week study in healthy volunteers (aged 20-65) demonstrated that supplementation with 21.5 mg of PQQ disodium salt was associated with improvements in lower limb extension strength and grip strength.36 These improvements were coupled with better performance on walking tests, suggesting that the biogenic effects of PQQ on muscle mitochondria translate into tangible physical outcomes.36

While these gains are likely to diminish if supplementation is ceased (due to the mitochondrial turnover discussed previously), the process of strengthening the muscle through improved bioenergetics may leave the individual in a better state than their initial baseline, particularly if the PQQ was used in conjunction with a rehabilitation or exercise program.36

### **Fat Oxidation and Weight Management**

PQQ has been shown to increase metabolic flexibility, promoting the use of fat for fuel.15 In animal models of high-fat diet-induced obesity, PQQ supplementation reduces visceral and hepatic fat accumulation by increasing fatty acid oxidation and energy expenditure.15 These metabolic shifts are driven by the upregulation of genes such as *CPT1a* and the downregulation of lipogenic genes like *Pparg*.33

## **Summary and Integrated Insights**

The cumulative evidence suggests that pyrroloquinoline quinone is a potent and safe metabolic regulator that operates primarily through the transient activation of the PGC-1$\\alpha$ biogenic cascade.6 When the substance is stopped, the biogenic "signal" for increased mitochondrial reproduction is removed, and the body returns to its genetically and environmentally determined basal state over the course of approximately one week.6 This return to baseline should not be confused with a negative downregulation or a withdrawal syndrome; it is the natural consequence of removing a bioactive stimulus that the body cannot produce on its own.1

### **Key Conclusions for Clinical Practice**

1. **Transient Biogenesis:** The increases in mitochondrial density and activity are dose-dependent and require ongoing supplementation to be maintained in adults.6  
2. **No Feedback Inhibition:** Because humans do not synthesize PQQ, exogenous supplementation does not suppress any endogenous production pathways.1  
3. **Corrective Downregulation:** PQQ is effective at downregulating pathological markers such as CRP, IL-6, and hyperphosphorylated Tau, which is a key therapeutic benefit during active use.22  
4. **NMDA Modulation:** PQQ provides a unique form of neuroprotection by oxidizing the NMDA receptor’s redox site, dampening excitotoxicity without inducing the side effects associated with receptor blockade.26  
5. **Maternal Persistence:** The only evidence for long-term, post-cessation persistence of PQQ's effects is in the context of developmental programming, where maternal supplementation can permanently improve the metabolic health of offspring.33  
6. **High Safety Margin:** PQQ has an excellent safety profile, with a NOAEL in rats of 600 mg/kg/day, which is vastly higher than the typical human supplemental dose of 0.15-0.30 mg/kg/day.11

In conclusion, for the standard adult user, PQQ does not induce lasting negative downregulations after stopping the substance. Instead, it offers a temporary biogenic and anti-inflammatory window that can be utilized to improve healthspan, with the system returning safely to baseline once the substance is cleared from the systemic circulation. The lack of rebound effects and the absence of feedback inhibition make it a particularly stable and predictable tool in the arsenal of mitochondrial and neuroprotective therapies.

#### **Works cited**

1. Pyrroloquinoline-Quinone Is More Than an Antioxidant: A Vitamin-like Accessory Factor Important in Health and Disease Prevention \- PMC, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC8533503/](https://pmc.ncbi.nlm.nih.gov/articles/PMC8533503/)  
2. Pyrroloquinoline quinone \- Wikipedia, accessed February 6, 2026, [https://en.wikipedia.org/wiki/Pyrroloquinoline\_quinone](https://en.wikipedia.org/wiki/Pyrroloquinoline_quinone)  
3. Pyrroloquinoline Quinone (PQQ): Its impact on human health and potential benefits, accessed February 6, 2026, [https://pubmed.ncbi.nlm.nih.gov/39513102/](https://pubmed.ncbi.nlm.nih.gov/39513102/)  
4. Generate Fresh Mitochondria with PQQ \- page 1 \- Life Extension, accessed February 6, 2026, [https://www.lifeextension.com/magazine/2011/2/generate-fresh-mitochondria-with-pqq](https://www.lifeextension.com/magazine/2011/2/generate-fresh-mitochondria-with-pqq)  
5. Potential Physiological Importance of Pyrroloquinoline Quinone \- ResearchGate, accessed February 6, 2026, [https://www.researchgate.net/profile/Robert-Rucker-2/publication/26869770\_Potential\_physiological\_importance\_of\_PQQ/links/0912f50609e366fa89000000/Potential-physiological-importance-of-PQQ.pdf](https://www.researchgate.net/profile/Robert-Rucker-2/publication/26869770_Potential_physiological_importance_of_PQQ/links/0912f50609e366fa89000000/Potential-physiological-importance-of-PQQ.pdf)  
6. PQQ Side Effects \- Michael Rucker, accessed February 6, 2026, [https://michaelrucker.com/functional-supplements/pqq-side-effects/](https://michaelrucker.com/functional-supplements/pqq-side-effects/)  
7. (PDF) 31 Pyrroloquinoline quinone and mitochondriogenesis \- ResearchGate, accessed February 6, 2026, [https://www.researchgate.net/publication/275952580\_31\_Pyrroloquinoline\_quinone\_and\_mitochondriogenesis](https://www.researchgate.net/publication/275952580_31_Pyrroloquinoline_quinone_and_mitochondriogenesis)  
8. Pyrroloquinoline quinone (PQQ) – an unproved supplement, accessed February 6, 2026, [https://pharmaceuticalintelligence.com/2015/10/15/pyrroloquinoline-quinone-pqq-an-unproved-supplement/](https://pharmaceuticalintelligence.com/2015/10/15/pyrroloquinoline-quinone-pqq-an-unproved-supplement/)  
9. Recent progress in studies on the health benefits of pyrroloquinoline quinone, accessed February 6, 2026, [https://www.researchgate.net/publication/280059358\_Recent\_progress\_in\_studies\_on\_the\_health\_benefits\_of\_pyrroloquinoline\_quinone](https://www.researchgate.net/publication/280059358_Recent_progress_in_studies_on_the_health_benefits_of_pyrroloquinoline_quinone)  
10. Pyrroloquinoline Quinone Stimulates Mitochondrial Biogenesis ..., accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC2804159/](https://pmc.ncbi.nlm.nih.gov/articles/PMC2804159/)  
11. Pyrroloquinoline-Quinone Is More Than an Antioxidant: A Vitamin-like Accessory Factor Important in Health and Disease Prevention \- MDPI, accessed February 6, 2026, [https://www.mdpi.com/2218-273X/11/10/1441](https://www.mdpi.com/2218-273X/11/10/1441)  
12. (PDF) Pyrroloquinoline Quinone Stimulates Mitochondrial Biogenesis through cAMP Response Element-binding Protein Phosphorylation and Increased PGC-1α Expression \- ResearchGate, accessed February 6, 2026, [https://www.researchgate.net/publication/38040626\_Pyrroloquinoline\_Quinone\_Stimulates\_Mitochondrial\_Biogenesis\_through\_cAMP\_Response\_Element-binding\_Protein\_Phosphorylation\_and\_Increased\_PGC-1a\_Expression](https://www.researchgate.net/publication/38040626_Pyrroloquinoline_Quinone_Stimulates_Mitochondrial_Biogenesis_through_cAMP_Response_Element-binding_Protein_Phosphorylation_and_Increased_PGC-1a_Expression)  
13. Pyrroloquinoline Quinone (PQQ) Attenuates Hydrogen Peroxide-Induced Injury Through the Enhancement of Mitochondrial Function in Human Trabecular Meshwork Cells \- MDPI, accessed February 6, 2026, [https://www.mdpi.com/1422-0067/26/14/6938](https://www.mdpi.com/1422-0067/26/14/6938)  
14. Regulation of Mitochondrial Biogenesis as a Way for Active Longevity: Interaction Between the Nrf2 and PGC-1α Signaling Pathways \- Frontiers, accessed February 6, 2026, [https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00435/full](https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2019.00435/full)  
15. Pyrroloquinoline-quinone to reduce fat accumulation and ameliorate obesity progression, accessed February 6, 2026, [https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2023.1200025/full](https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2023.1200025/full)  
16. Effects of PQQ administration on molecular regulation of mitochondrial... \- ResearchGate, accessed February 6, 2026, [https://www.researchgate.net/figure/Effects-of-PQQ-administration-on-molecular-regulation-of-mitochondrial-content-in-vivo-A\_fig4\_373773199](https://www.researchgate.net/figure/Effects-of-PQQ-administration-on-molecular-regulation-of-mitochondrial-content-in-vivo-A_fig4_373773199)  
17. Does PQQ influence mitochondrial biogenesis through the Nrf2/HO-1 signaling pathway?, accessed February 6, 2026, [https://consensus.app/search/does-pqq-influence-mitochondrial-biogenesis-throug/9SCjuhB8Sm2bN-uD-QTKoQ/](https://consensus.app/search/does-pqq-influence-mitochondrial-biogenesis-throug/9SCjuhB8Sm2bN-uD-QTKoQ/)  
18. Does PQQ promote mitochondrial biogenesis via the Nrf2/HO-1 pathway? \- Consensus, accessed February 6, 2026, [https://consensus.app/search/does-pqq-promote-mitochondrial-biogenesis-via-the-/\_JPchvdCTzm5DrNGESgpww/](https://consensus.app/search/does-pqq-promote-mitochondrial-biogenesis-via-the-/_JPchvdCTzm5DrNGESgpww/)  
19. Metabolic and Biochemical Effects of Pyrroloquinoline Quinone (PQQ) on Inflammation and Mitochondrial Dysfunction: Potential Health Benefits in Obesity and Future Perspectives \- MDPI, accessed February 6, 2026, [https://www.mdpi.com/2076-3921/13/9/1027](https://www.mdpi.com/2076-3921/13/9/1027)  
20. Pyrroloquinoline quinone enhances the resistance to oxidative stress and extends lifespan upon DAF-16 and SKN-1 activities in C. elegans | Request PDF \- ResearchGate, accessed February 6, 2026, [https://www.researchgate.net/publication/301319467\_Pyrroloquinoline\_quinone\_enhances\_the\_resistance\_to\_oxidative\_stress\_and\_extends\_lifespan\_upon\_DAF-16\_and\_SKN-1\_activities\_in\_C\_elegans](https://www.researchgate.net/publication/301319467_Pyrroloquinoline_quinone_enhances_the_resistance_to_oxidative_stress_and_extends_lifespan_upon_DAF-16_and_SKN-1_activities_in_C_elegans)  
21. Pyrroloquinoline Quinone (PQQ) Nutritional Status in Humans after Oral Supplementation, accessed February 6, 2026, [https://www.researchgate.net/publication/352432182\_Pyrroloquinoline\_Quinone\_PQQ\_Nutritional\_Status\_in\_Humans\_after\_Oral\_Supplementation](https://www.researchgate.net/publication/352432182_Pyrroloquinoline_Quinone_PQQ_Nutritional_Status_in_Humans_after_Oral_Supplementation)  
22. Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation and mitochondrial-related metabolism in human subjects \- PubMed, accessed February 6, 2026, [https://pubmed.ncbi.nlm.nih.gov/24231099/](https://pubmed.ncbi.nlm.nih.gov/24231099/)  
23. Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation and mitochondrial-related metabolism in human subjects \- ResearchGate, accessed February 6, 2026, [https://www.researchgate.net/publication/258526667\_Dietary\_pyrroloquinoline\_quinone\_PQQ\_alters\_indicators\_of\_inflammation\_and\_mitochondrial-related\_metabolism\_in\_human\_subjects](https://www.researchgate.net/publication/258526667_Dietary_pyrroloquinoline_quinone_PQQ_alters_indicators_of_inflammation_and_mitochondrial-related_metabolism_in_human_subjects)  
24. Sulfur | Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA, accessed February 6, 2026, [https://pharmaceuticalintelligence.com/tag/sulfur/](https://pharmaceuticalintelligence.com/tag/sulfur/)  
25. PQQ ameliorates D-galactose induced cognitive impairments by ..., accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5995849/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5995849/)  
26. Novel Role for the NMDA Receptor Redox Modulatory Site in the Pathophysiology of Seizures \- NIH, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6772486/](https://pmc.ncbi.nlm.nih.gov/articles/PMC6772486/)  
27. Interaction of the putative essential nutrient pyrroloquinoline quinone with the N-methyl-D-aspartate receptor redox modulatory site \- PubMed, accessed February 6, 2026, [https://pubmed.ncbi.nlm.nih.gov/1318959/](https://pubmed.ncbi.nlm.nih.gov/1318959/)  
28. Further evidence that pyrroloquinoline quinone interacts with the N-methyl-D-aspartate receptor redox site in rat cortical neurons in vitro \- PubMed, accessed February 6, 2026, [https://pubmed.ncbi.nlm.nih.gov/7518062/](https://pubmed.ncbi.nlm.nih.gov/7518062/)  
29. Neuroprotection \- Wikipedia, accessed February 6, 2026, [https://en.wikipedia.org/wiki/Neuroprotection](https://en.wikipedia.org/wiki/Neuroprotection)  
30. Modulating NMDA receptors to treat MK-801-induced schizophrenic ..., accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7060539/](https://pmc.ncbi.nlm.nih.gov/articles/PMC7060539/)  
31. Powerful Protection Against Cellular Aging \- page 1 \- Life Extension, accessed February 6, 2026, [https://www.lifeextension.com/magazine/2012/10/powerful-protection-against-cellular-aging](https://www.lifeextension.com/magazine/2012/10/powerful-protection-against-cellular-aging)  
32. Pyrroloquinoline Quinone (PQQ) Inhibits Lipopolysaccharide Induced Inflammation in Part via Downregulated NF-κB and p38/JNK Activation in Microglial and Attenuates Microglia Activation in Lipopolysaccharide Treatment Mice | PLOS One \- Research journals, accessed February 6, 2026, [https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0109502](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0109502)  
33. Early PQQ supplementation has persistent long-term protective effects on developmental programming of hepatic lipotoxicity and inflammation in obese mice \- PMC, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC5349805/](https://pmc.ncbi.nlm.nih.gov/articles/PMC5349805/)  
34. Early PQQ supplementation has persistent long-term protective effects on developmental programming of hepatic lipotoxicity and inflammation in obese mice | Request PDF \- ResearchGate, accessed February 6, 2026, [https://www.researchgate.net/publication/311855464\_Early\_PQQ\_supplementation\_has\_persistent\_long-term\_protective\_effects\_on\_developmental\_programming\_of\_hepatic\_lipotoxicity\_and\_inflammation\_in\_obese\_mice](https://www.researchgate.net/publication/311855464_Early_PQQ_supplementation_has_persistent_long-term_protective_effects_on_developmental_programming_of_hepatic_lipotoxicity_and_inflammation_in_obese_mice)  
35. Maternal high-fat diet programs | JIR \- Dove Medical Press, accessed February 6, 2026, [https://www.dovepress.com/maternal-high-fat-diet-programs-renal-peroxisomes-and-activates-nlrp3--peer-reviewed-fulltext-article-JIR](https://www.dovepress.com/maternal-high-fat-diet-programs-renal-peroxisomes-and-activates-nlrp3--peer-reviewed-fulltext-article-JIR)  
36. Efficacy and safety of a novel dietary pyrroloquinoline quinone ..., accessed February 6, 2026, [https://www.researchgate.net/publication/377885819\_Efficacy\_and\_safety\_of\_a\_novel\_dietary\_pyrroloquinoline\_quinone\_disodium\_salt\_on\_muscle\_strength\_and\_physical\_function\_in\_healthy\_volunteers\_A\_randomized\_double-blind\_placebo-controlled\_study](https://www.researchgate.net/publication/377885819_Efficacy_and_safety_of_a_novel_dietary_pyrroloquinoline_quinone_disodium_salt_on_muscle_strength_and_physical_function_in_healthy_volunteers_A_randomized_double-blind_placebo-controlled_study)  
37. Pyrroloquinoline Quinone (PQQ): Exploring its Impact on Human Health and Potential Benefits | Request PDF \- ResearchGate, accessed February 6, 2026, [https://www.researchgate.net/publication/385148862\_Pyrroloquinoline\_Quinone\_PQQ\_Exploring\_its\_Impact\_on\_Human\_Health\_and\_Potential\_Benefits](https://www.researchgate.net/publication/385148862_Pyrroloquinoline_Quinone_PQQ_Exploring_its_Impact_on_Human_Health_and_Potential_Benefits)  
38. Pyrroloquinoline quinone may improve cognition in healthy older adults \- Study Summary, accessed February 6, 2026, [https://examine.com/research-feed/study/0O4Rk9/](https://examine.com/research-feed/study/0O4Rk9/)  
39. PQQ boosts brain function in older and younger generations \- Research Features, accessed February 6, 2026, [https://researchfeatures.com/wp-content/uploads/2023/10/Kazuto-Ikemoto-1.pdf](https://researchfeatures.com/wp-content/uploads/2023/10/Kazuto-Ikemoto-1.pdf)  
40. Study Details | NCT07148726 | EFFECTS OF PYRROLOQUINOLINE QUINONE (PQQ) SUPPLEMENTATION ON NON-ENDURANCE TRAINED ATHLETES | ClinicalTrials.gov, accessed February 6, 2026, [https://clinicaltrials.gov/study/NCT07148726](https://clinicaltrials.gov/study/NCT07148726)  
41. Pyrroloquinoline Quinone (PQQ): Its impact on human health and potential benefits, accessed February 6, 2026, [https://pmc.ncbi.nlm.nih.gov/articles/PMC11541945/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11541945/)  
42. Effect of Dietary Pyrroloquinoline Quinone Disodium Salt on Cognitive Function in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study \- ResearchGate, accessed February 6, 2026, [https://www.researchgate.net/publication/354036929\_Effect\_of\_Dietary\_Pyrroloquinoline\_Quinone\_Disodium\_Salt\_on\_Cognitive\_Function\_in\_Healthy\_Volunteers\_A\_Randomized\_Double-Blind\_Placebo-Controlled\_Parallel-Group\_Study](https://www.researchgate.net/publication/354036929_Effect_of_Dietary_Pyrroloquinoline_Quinone_Disodium_Salt_on_Cognitive_Function_in_Healthy_Volunteers_A_Randomized_Double-Blind_Placebo-Controlled_Parallel-Group_Study)

[image1]: <data:image/png;base64,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>

[image2]: <data:image/png;base64,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>

[image3]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABkAAAAUCAYAAAB4d5a9AAABS0lEQVR4Xu2UMStGURjH/4oiShallMsgBqUMymCyGJRCST6AjBYfwCIxKywG5QuYFMposxtITEwsSvyezj1v955z3ku9Gd7yq99wn/M89zn3ufce6Z9mIMPlMFiHedwJg9CBK3igwvooruMFfuKxX6ggwzvFud14jlvYheN+wZrYrqbwUXFhSBse4Zfi3E28wZ4gXqMP7xUXhizhnuIN2Y2tQWX9b5pkcrMeUZxrE3kJYhE/NbEx7eKk0rkT+B7EIlKFRRZwA1uUzp1T+j2VSBV6BvBQ7usxUrmzaqBJK27LjcmTym1oXL14jQ8Fn+R2/ZFfr+EQPiuuL1GvSYpUrv18V3iG7YV4CV94Ivdyq+iX+0/C3FW5JxvMr2trM3IFdqTYCMw3vMUxn5TTiadyY/K5r3LjMuwz38dLuVPEjpc/wXY/jIs4Haw1Md/wQFObPhPZLgAAAABJRU5ErkJggg==>

[image4]: <data:image/png;base64,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>

[image5]: <data:image/png;base64,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>

[image6]: <data:image/png;base64,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>

[image7]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAgAAAAVCAYAAAB7R6/OAAAAoUlEQVR4XmNgGDzAA4gXAbEOEEuiYTAoB+L/ODAYzAHi9UA8CwnPBuIHIEkeIJ4OxCJQxTBgDsSLQQxOKIcFSVIMiNcAsTySGByAFE4C4nB0CRggqMAWiHcDMT+6BAiAdC9ngJiAFYAC6j0QR6NLwEA6AyRwfNElYAAUYL+B2AZdAgQ4gHgrEH8FYmM0OTDgBuI9DHgUgAAo5EDGM6NLkA8AKhYcgqASEY4AAAAASUVORK5CYII=>

[image8]: <data:image/png;base64,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>

[image9]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAoAAAAVCAYAAAB/sn/zAAAAtklEQVR4XmNgGAW0APJArIsmxgzEvMgCPEB8AIiXAjEjkngDEF9E4jMoAfFzIC5CEuMG4j0MEM1w4AfEP4HYBkkMpjkdSYxhEhDfBWJxJDEMzTD3rQFiFpggELQyoGnWBOK3QFwFE2BA1QxigwHIiv8MEBNgIBiI/zJANOvABEHu+wfE74G4HYhXAHEdEM8F4lNAvBykCN0KSSgNAqDwFIbxYe5DDj+sACMIcAGQSaAoAlmBEwAAzFgiOFP/yNQAAAAASUVORK5CYII=>

[image10]: <data:image/png;base64,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>

[image11]: <data:image/png;base64,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>

[image12]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAgAAAAVCAYAAAB7R6/OAAAAtElEQVR4XmNgGFxAEohrgXgWEDcCsQqypBkQ7wZiWyDWB+KtQPwfiItBkpxAvAGIk4CYGapBGIhPAfFXEAdk9EMg/sQA0Q0DVQwQUxhYgXgiEO9kgCiGgXKYAmyABYjXAPFfdAkYIKjAnAHiQJCXMQA/EO8B4sVAzI0mB3bwDCDuY4B4HwXAJCsZEOGhCZNkZICEWiGUDQPpMMkEIP4GxE+A+BESfgdSAAtJUKCg4+cgBTQGAJtzJcOGdyfuAAAAAElFTkSuQmCC>

[image13]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAgAAAAVCAYAAAB7R6/OAAAAy0lEQVR4Xs3RsQtBURTH8SspJSRWqwyKsssmi8lgNxglg9losBhNJOUfsCsbfwIWg02iLEp873vnEDJZ/OpT975z6tx7nzH/lRDq6KONBDxaTGOGPCKo4YKmNvRwRUn2tmmJvTZ0cUNV9kHMcdIGH2Lwyj6Fg3HHfsQedowtMm81J18bAphIYYOCeY78SBI7jN4LGvtAdoy9mXODhrBrTUsbsjgLu9YMtSGOFQYISzGKhXHfwkkRa3RQwRRH+f6I37g/q4yceT3PD7kDGAsmV2S4An4AAAAASUVORK5CYII=>

[image14]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAgAAAAVCAYAAAB7R6/OAAAAuUlEQVR4XmNgGDxAAYijgFgGiJmBmAOI9YE4DabACoh/AvF/JPwViL1hCoyB+BoQ3wDiC0DcCMSSMEmYgsnIAuiAKAXrgXgREN8B4kdAXA/EnCQpOAnEKlC+MBCfAuJZMAWsQMwN40BBFQPE6zhBOQMkPMDGnQbiK0Ashk0BKEAeYlEAsgKsgAWIZwCxOZIkPxAfAuI9MAF5ID4MxN1AnAzE54H4GAMk8uAA5BM7IA4BYk0GSKxSAQAA8Qwl4dm9I84AAAAASUVORK5CYII=>

[image15]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAADYAAAAUCAYAAADGIc7gAAAAn0lEQVR4Xu3TsQnCQBiG4RO1SieiCJbiAlYOIFlAsFfsLOMIjmDpANpnB6u0gfQZI+B7eCGXG0AO+V54OPj5i4NLjFFKKaWU+nUDHFCjwRPL3kZXgnM4jLUdcqwxwwkltv6Sa45LOIyxEW7me2G/Fd44Yuhm9syQtksxN8U1HLomeKHCAwXuGPtLsWYvuQiHXvb/s5/oHhvTvZ5SSv1fH4gqDj7b9TQ9AAAAAElFTkSuQmCC>

[image16]: <data:image/png;base64,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>

[image17]: <data:image/png;base64,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>

[image18]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABEAAAAUCAYAAABroNZJAAAA7UlEQVR4XmNgGAXEAAUgjkAXRALqQNwFxLOAOAqIOWESmkCcBcT7gPgvEC+ESaCBYCC+BsQGQMwDxM1AvBsmCTIkAIitgPgJA3ZDZIH4NhBHI4kJAvFpJD4YSALxQwbshoA0fwViYyQxRiBeisQHA3yGTGLANAQEMNTiMwQkRpEhoEA8wEChIdxAvIeBQkNAgGLvgEArAxUM8WOAJEQXJDEOIN6KxAcDmCGguGdEkxMG4lNA3IAkpsIASZxgADIdxAHZ9B+KvwDxJSDWhSkCAhMgvg/EZUAcwgBJrZ1I8kQDUEy5MUCyCSgrDCIAACuZOhkWxF1nAAAAAElFTkSuQmCC>

[image19]: <data:image/png;base64,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>

[image20]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABEAAAAUCAYAAABroNZJAAABLElEQVR4Xu2TvyuFYRTHj1B0lURkuFmUlEFRFjbJcqUoxR/gP2BVMjBaFBYkizKZGMzsFgODVSaTxOd7z33vPffh6h0NvvWp5znnPN/nx3tes3810iwcwwj0J/RBa63UhmAH9mEZ2rPEOnw24AWGK3ULcA+j0AGbcFXJ2SFcmLtnHMATrEETFOEBVnxJWV1wp4Ec96AnJKUJOLHacbX4DcaqFW5+qoGKtKAlJHvhHAZCbNe+m0hHybwsmWnBUhJXcW6TKfPH6gwxXfnGcproFGfmJ4kqwLXlNFGfvFr9F8iU+zqr5r1RShNoy3KaqF/eYTJNoDn4gOkQa4PLMK8GftpN6oZb2AixQXgO818fL9M4PJp38aJ5t27XVZg3l67SnCaCtNkMzJv/Cn9IX1k5PTIq7baiAAAAAElFTkSuQmCC>

[image21]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAgAAAAVCAYAAAB7R6/OAAAATElEQVR4XmNgGJxAAYgj0AU1gTgLiPcB8V8gXogqDVEQAMRWQPyEAYsCGJAE4ocMowqIVrAUiBmRJVwYIEEMiof/UPwFiC8hK6IRAADdtBucV5d4zQAAAABJRU5ErkJggg==>

[image22]: <data:image/png;base64,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>

[image23]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAwAAAAZCAYAAAAFbs/PAAAA20lEQVR4Xu3RL4sCQRzG8Z94giaDf0FFDAa7UTgxaTAr+AIsNoPBeyXHidGgYBDkXoKYDYLBYrUc2AT9jjNzzlrEZtgHPrA8v9nZ3VkRP++aFJqoIuwdeZPGDHO0McQBZTPPoGiuJY8NvhEy3Qcm+EUEX6jYwY/o3Qpmsc0Af6hjjKgqX76hhKPo91c3u+ngJHpxy5bqRC7o2sKJnS1Ef8ctDVOq4WNUd8anW+awQ8/pAqhhK/fNsojbBWq4xxQjrNBHAkusRR+vOv7/BJFETPQT3F7tbP+Pn6e5ApPEJUHhfTdnAAAAAElFTkSuQmCC>

[image24]: <data:image/png;base64,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>

[image25]: <data:image/png;base64,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>

[image26]: <data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAACMAAAAUCAYAAAAHpoRMAAAAr0lEQVR4XmNgGAWjYIQAPiCuAeJDQKyMJkc3IAzE3UB8GIidgJgZVZo+QBGI5zJAQsIciBlRpekD1IF4NRRrMQyAI0AWgny/nQESGqBQGTDgD8SfgDiIYQBCAhsYFAkVHcCy8AkGSIgNCkdxA3E+EJ8D4jgg5kSVHhjACsQRDBBHgRwHcuSAA1B0gaJtBxCroMmNAroAULoQB2JJIrAYA41zmAEQzyIS9zJAHEV1AAAUchlzAh2bXgAAAABJRU5ErkJggg==>